Ex Vivo Inhibition of Platelet Aggregation in Patients with Severe Limb Arteriopathy Treated with BAY U3405, a Specific IX A₂ Receptor Antagonist

Summary

A double-blind, placebo-controlled randomized study with BAY U3405, a specific thromboxane A₂ (TX A₂) receptor blocker, was performed in patients suffering from severe stade II limb arteriopathy. BAY U3405 or placebo was administered in 16 patients at 20 mg four times a day (from day 1 to day 3). Hemostatic studies were done before therapy, and on day 2 and day 3 under therapy. On day 3, BAY U3405 was shown to induce a highly statistically significant decrease of the velocity and the intensity of the aggregations mediated by arachidonic acid (56 ± 37% for the velocity, 58 ± 26% for the intensity) or by U46619 endoperoxide analogue (36 ± 35% for the velocity, 37 ± 27% for the intensity). Similar results were already observed on day 2. By contrast, such a decrease was not noticed with ADP mediated platelet aggregation. Furthermore, plasma levels of betathrombo-globulin and platelet factor 4 remained unchanged. Peripheral hemodynamic parameters were also studied. The peripheral blood flow was measured using a Doppler ultrasound; the pain free walking distance and the total walking ability distance were determined under standardized conditions on a treadmill. These last two parameters show a trend to improvement which nevertheless was not statistically significant. All together these results encourage further in vivo studies using BAY U3405 or related compounds on a long-term administration.

• References

• 1 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
• 2 Granstrom E, Diczfalusy U, Hamberg M, Hansson G, Malmsten C, Samuelsson B. Thromboxane A2: biosynthesis and effects on platelets. Prostaglandins and the cardiovascular system Samuelsson B, Paoletti R, Ramwell P. eds. In: Advances in Prostaglandin, Thromboxane and Leu-kotriene Research. Raven Press; New York: 1982. 10 15-18
• 3 Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979; 300: 1142-1147
• 4 Kennedy I, Coleman RA, Humphrey PPA, Levy GP, Lumley P. Studies on the characterization of prostanoid receptors: a proposed classification. Prostaglandins 1982; 24: 667-689
• 5 Halushka PV, Mais DE, Saussy Jr DL. Platelet and vascular smooth muscle thromboxane A2/Prostaglandin H2 receptors. Fed Proc 1987; 46: 149-153
• 6 Brass LF, Shaller CC, Belmonte EJ. Inositol triphosphate induced granule secretion from platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein dependent mechanism distinct from that of thrombin. J Clin Invest 1987; 79: 1269-1275
• 7 Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989; 74: 1181-1195
• 8 Seuter F, Perzbom E, Fiedler VB, Rosentreter U, Boshagen H. Inhibition of platelet aggregation by a novel thromboxane antagonist BAY U3405. XIIth Congress of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1989; 62: 345A
• 9 Perzbom E, Fiedler VB, Seuter F, Stasch JP, Weber H, Sander E, Boshagen H, Rosentreter U. Characterization of BAY U3405, a novel thromboxane A2/endoperoxide receptor antagonist. Stroke 1990; 21 (Suppl IV) 143-145
• 10 Fiedler VB, Seuter F, Perzbom E. Effect of the novel thromboxane antagonist BAY U3405 on experimental coronary artery disease. Stroke 1990; 21 (Suppl IV) 149-151
• 11 Seuter F, Perzbom E, Fiedler VB. Effect of BAY U3405, a new thromboxane antagonist, on collagen-induced thrombo-embolism in rabbits. Stroke 1990; 21 (Suppl IV) 146-148
• 12 Francis HP, Greenham SJ, Patel UP, Thompson AM, Gardiner PJ. BAY U3405, an antagonist of thromboxane A2 and prostaglandin D2 induced bronchoconstriction in the guinea-pig. Brit J Pharmacol 1991; 104: 596-602
• 13 Drouet L, Bal C, Pignaud G, Thiam-Cisse M. Comparative antithrombotic effects of aspirin and a thromboxane A2 antagonist in vivo in the guinea-pig. XIIth Congress of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1991; 65: 1357-2408A
• 14 Fiedler VB, Perzbom E, Seuter F. Protective effect of a novel thromboxane antagonist BAY U3405, on canine myocardial damage after coronary artery occlusion and reperfusion. Pharmacotherapy 1991; 11: 77-84
• 15 Weber H, Ritter W, Perzbom E, Horstmann R, Kuhlmann J. Tolerability and pharmacodynamic effects of the thromboxane A2 antagonist BAY U3405 in healthy volunteers. J Clin Pharmacol 1990; 30: 849-875 Abstr
• 16 Kaplan KL, Owen J. Plasma levels of beta thromboglobulin and Platelet Factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
• 17 Mielke CH, Kaneshiro MM. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-209
• 18 Dimitriadou C, Sultan Y, Levy-Toledano S, Bemal-Hoyos E, Caen JP. Etude du temps de saignement quantitatif et des fonctions plaquettaires au cours des purpuras thrombopeniques. Nouv Press Med 1974; 3 (22) 1425-1428
• 19 Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 420-425
• 20 Fitzgerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane A2 biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1177
• 21 Fitzgerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068
• 22 Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989
• 23 Kroll MH, Zavoico GB, Schafer AI. Second messenger function of phosphatidic acid in platelet activation. J Cell Physiol 1989; 139: 558-564
• 24 Kinlough-Rathbone RL, Packham MA, Mustard JF. Synergism between platelet aggregating agents: the role of the arachidonate pathway. Thromb Res 1977; 11: 567-580
• 25 Ludlam CA, Cash JD. Studies on the liberation of beta-thromboglobulin from human platelets in vitro. Brit J Hematol 1976; 247: 239-247
• 26 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol) 1971; 231: 232-235
• 27 Preston FE, Whipps S, Jackson CA, French AJ, Wyld PJ, Stoddard CJ. Inhibition of prostacyclin and thromboxane A2 after low-dose aspirin. N Engl J Med 1981; 304: 76-79
• 28 Fitzgerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688
• 29 Gresele P, Amout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis Studies with combined thromboxane synthetase inhibition and thromboxane receptor antagonism. J Clin Invest 1987; 80: 1435-1415
• 30 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res 1982; 26: 389-400
• 31 Defreyn G, Machin SJ, Carreras LO, Dauden MV, Chamone DAF, Vermylen J. Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism. BrJ Haematol 1981; 49: 29-41
• 32 Foster MR, Hornby EJ, Stratton LE. Effect of GR 32191 and other thromboxane receptor blocking drugs on human platelet deposition onto de-endothelialized arteries. Thromb Res 1992; 65: 769-784
• 33 Hornby EJ, Foster MR, McCabe PJ, Stratton LE. The inhibitory effect of GR 32191, a thromboxane receptor blocking drug, on human platelet aggregation adhesion and secretion. Thromb Haemost 1989; 61: 429-436